Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Liabilities and Shareholders Equity (2021 - 2025)

Krystal Biotech (KRYS) has disclosed Liabilities and Shareholders Equity for 5 consecutive years, with $1.3 billion as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 26.33% to $1.3 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.8 billion through Dec 2025, up 25.66% year-over-year, with the annual reading at $1.3 billion for FY2025, 26.33% up from the prior year.
  • Liabilities and Shareholders Equity hit $1.3 billion in Q4 2025 for Krystal Biotech, up from $1.2 billion in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.3 billion in Q4 2025 to a low of $443.0 million in Q1 2021.
  • Historically, Liabilities and Shareholders Equity has averaged $786.9 million across 5 years, with a median of $737.2 million in 2023.
  • Biggest five-year swings in Liabilities and Shareholders Equity: dropped 13.78% in 2023 and later skyrocketed 60.44% in 2024.
  • Year by year, Liabilities and Shareholders Equity stood at $626.3 million in 2021, then fell by 10.83% to $558.4 million in 2022, then skyrocketed by 46.54% to $818.4 million in 2023, then increased by 29.02% to $1.1 billion in 2024, then increased by 26.33% to $1.3 billion in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for KRYS at $1.3 billion in Q4 2025, $1.2 billion in Q3 2025, and $1.1 billion in Q2 2025.